Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Upgraded by StockNews.com

by · The Cerbat Gem

StockNews.com upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) from a sell rating to a hold rating in a research report released on Wednesday morning.

MRNS has been the topic of several other reports. Truist Financial reaffirmed a buy rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Cantor Fitzgerald restated an overweight rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright reaffirmed a buy rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, August 14th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $9.20.

Read Our Latest Stock Analysis on MRNS

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $1.66 on Wednesday. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68. The stock has a fifty day moving average of $1.38 and a 200 day moving average of $2.82. The firm has a market capitalization of $91.19 million, a price-to-earnings ratio of -0.63 and a beta of 1.13. Marinus Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The company had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. During the same period in the prior year, the business posted ($0.61) earnings per share. As a group, research analysts expect that Marinus Pharmaceuticals will post -1.88 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNS. Point72 DIFC Ltd purchased a new stake in shares of Marinus Pharmaceuticals in the second quarter worth $28,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Marinus Pharmaceuticals in the 2nd quarter worth about $64,000. AQR Capital Management LLC grew its position in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at about $206,000. Finally, XTX Topco Ltd bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at about $232,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Articles